Project 1An innovative solution for monitoring graft rejection after transplantation. Every year 100,000 patients undergo organ transplantation all over the world as the only definitive treatment for end-stage organ failure. Independently on the organ transplanted, graft rejection is a major open problem for these patients, occurring when the graft is recognized as foreign, attacked and rejected by the recipient's immune system, causing cellular damage and graft failure. Postoperative care consists of a painful surveillance that lasts a lifetime, with frequent organ biopsies, necessary to guarantee a survival rate of 15 years.
MWG is developing a new and non invasive tool for monitoring rejection, a marketable solution for reliable, safe and non-invasive monitoring of allograft damage, which will allow the monitoring of transplanted patients’ rejection, since early onset and drastically lower the need of frequent organ biopsies.